Press Release Archive
May 15, 2006
Epeius Biotechnologies To Present The Advent Of Tumor Targeting Technology And The Clinical Development Of Its Lead Anti-Cancer Agent, Rexin-G™, At Upcoming Bioventure, Nanotechnology & Nanomedicine Conferences .
May 15, 2007 PDF Version
December 6, 2006
Japanese study confirms safety and efficacy of intravenous Rexin-G™ as treatment for diverse metastatic cancers.
December 6, 2006 PDF Version (28kb)
October 10, 2006
Epeius Biotechnologies affirms leadership role in the development of genetic medicine: accepts invitations to speak at two prestigious industry conferences.
October 10, 2006 PDF Version (26kb)
October 2, 2006
Epeius Biotechnologies gains federal support for landmark clinical trials of tumor-targeted gene therapy using Rexin-G.
October 2, 2006 PDF Version (24.8kb)
August 10, 2006
Epeius Biotechnologies receives accelerated approval for Rexin-G in the Philippines
August 10, 2006 PDF Version (23.8kb)
July 4, 2006
Epeius Biotechnologies initiates Tri-Rex vaccination protocols for breast cancer.
July 4, 2006 PDF Version (27.1kb)
June 19, 2006
Epeius Biotechnologies receives $400,000 grant to support gene therapy trials for pancreatic cancer.
June 19, 2006 PDF Version (24.1kb)
April 7, 2006
Expanded access program for Rexin-G™ provides genetic medicine to cancer patients, first revenues for Epeius Biotechnologie
April 7, 2006 PDF Version (15kb)
April 4, 2006
Epeius Biotechnologies establishes corporate headquarters in San Marino, California - Facilities include a Clinical Research Unit dedicated to evaluating new genetic medicine for cancer.
April 4, 2006 PDF Version (44.6kb)
July 14, 2005
Clinical Trial for pancreatic cancer opens at Mayo Clinic using tumor-targeted gene therapy vector Rexin-G™, the world's first tumor-targeted gene delivery vector.
July 14, 2005 PDF Version (13.9kb)
April 4, 2005
Phase I Clinical Trial for advanced colon and pancreatic cancer opens in New York using Rexin-G™, the world's first tumor-targeted gene delivery vector.
April 4, 2005 PDF Version (6.5kb)
May 11, 2004
First American Gains Therapeutic Benefit From REXIN-G™, the leading tumor-targeted Gene Therapy Vector for Pancreatic Cancer.
May 11, 2004 PDF Version (93.8kb)
August 22, 2003
Epeius Biotechnologies corporation gains FDA orphan drug approval for Rexin-G™, the world's first targeted injectable gene therapy vector, for Pancreatic Cancer.
August 22, 2003 PDF Version (77kb)
June 3, 2003
Epeius Biotechnologies Corporation today announced that clinical trials have started in Manila, testing the world's first targeted injectable gene delivery system for treating metastatic cancer, using Epeius' TDS technologies.
June 3, 2003 PDF Version (17.8kb)
Medical Observer (874.6kb)
December 2005, p.27
Molecular Engineering of a "Pathotropic" Targeting for Cancer Gene Therapy (211.2kb)
Bioprocessing Journal Jan/Feb 2004
Technology Evaluation: Rexin-G By Michael Morse (56.6kb)
Current Opinion in Molecular Therapeautics 2005 7(2):164-169
Inhibition of Metastatic Tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 Construct (1.6MB)
Cancer Research 2000 60:3343-3347
First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. (213kb)
International Journal of Oncology 2004 24:177-185
You must have Adobe Acrobat Reader to view PDF files. You may download it for free by clicking here.